The IMPACT trial compared sipuleucel-T to standard of care in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Sipuleucel-T improved median OS (25.8 vs. 21.7 mo) and 3-yr OS (31.7% vs. 23.0%). (KantoffPW et al., NEJM 2010)